Herpes simplex encephalitis: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
mNo edit summary
 
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{DiseaseDisorder infobox |
{{DiseaseDisorder infobox |
   Name        = Herpesviral encephalitis |
   Name        = Herpesviral encephalitis |
Line 9: Line 10:


==Overview==
==Overview==
Herpes simplex encephalitis is a severe [[viral infection]] of the [[central nervous system]]. Herpes simplex encephalitis may be classified according to origin of disease into two subtypes: oral ([[herpes simplex virus|HSV-1]]) and genital ([[herpes simplex virus|HSV-2]]). The exact pathogenesis of herpes simplex encephalitis is not fully understood.<ref name=Schlossberg> Schlossberg D. Clinical Infectious Disease. Cambridge University Press; 2008.</ref> Herpes simplex encephalitis must be differentiated from other diseases that cause [[fever]], [[headache]], and [[altered mental status]]. Physical examination findings for herpes simplex encephalitis are generally unspecific. Herpes simplex encephalitis constitutes a [[medical emergency]]. If left untreated, approximately 70% patients with herpes simplex encephalitis progress to [[mortality]].<ref name="pmid16675036">{{cite journal |author=Whitley RJ |title=Herpes simplex encephalitis: adolescents and adults |journal=Antiviral Res. |volume=71 |issue=2-3 |pages=141–8 |year=2006 |pmid=16675036 |doi=10.1016/j.antiviral.2006.04.002}}</ref> Common complications of herpes simplex encephalitis include [[meningitis]], increased [[intracranial pressure]], and [[coma]]. Laboratory findings consistent with the diagnosis of herpes simplex encephalitis include increased [[leukocytes]] in [[cerebrospinal fluid]].<ref name="pmid11853816">{{cite journal |author=Whitley RJ, Gnann JW |title=Viral encephalitis: familiar infections and emerging pathogens |journal=Lancet |volume=359 |issue=9305 |pages=507–13 |year=2002 |pmid=11853816 |doi=}}</ref> [[Polymerase chain reaction]] is critical in the diagnosis of herpes simplex encephalitis, as there is a 95-98% specificity and sensitivity beginning as early as one day after symptoms first appear and lasting up to one week after treatment.<ref name=Schlossberg> Schlossberg D. Clinical Infectious Disease. Cambridge University Press; 2008.</ref> [[Magnetic resonance imaging]] is the imaging modality of choice for herpes simplex encephalitis. The mainstay of therapy for herpes simplex encephalitis includes [[antiviral drug|antiviral]] therapy. The drug of choice is [[acyclovir]].<ref name=Mandell1> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref>  
Herpes simplex encephalitis is a severe [[viral infection]] of the [[central nervous system]]. Herpes simplex encephalitis may be classified according to the origin of the disease into two subtypes: oral ([[herpes simplex virus|HSV-1]]) and genital ([[herpes simplex virus|HSV-2]]). The exact pathogenesis of herpes simplex encephalitis is not fully understood.<ref name="Schlossberg"> Schlossberg D. Clinical Infectious Disease. Cambridge University Press; 2008.</ref> Herpes simplex encephalitis must be differentiated from other diseases that cause [[fever]], [[headache]], and [[altered mental status]]. Physical examination findings for herpes simplex encephalitis are generally unspecific. Herpes simplex encephalitis constitutes a [[medical emergency]]. If left untreated, approximately 70% patients with herpes simplex encephalitis progress to [[mortality]].<ref name="pmid16675036">{{cite journal |author=Whitley RJ |title=Herpes simplex encephalitis: adolescents and adults |journal=Antiviral Res. |volume=71 |issue=2-3 |pages=141–8 |year=2006 |pmid=16675036 |doi=10.1016/j.antiviral.2006.04.002}}</ref> Common complications of herpes simplex encephalitis include [[meningitis]], increased [[intracranial pressure]], and [[coma]]. Laboratory findings consistent with the diagnosis of herpes simplex encephalitis include increased [[leukocytes]] in [[cerebrospinal fluid]].<ref name="pmid11853816">{{cite journal |author=Whitley RJ, Gnann JW |title=Viral encephalitis: familiar infections and emerging pathogens |journal=Lancet |volume=359 |issue=9305 |pages=507–13 |year=2002 |pmid=11853816 |doi=}}</ref> [[Polymerase chain reaction]] is critical in the diagnosis of herpes simplex encephalitis, as there is a 95-98% specificity and sensitivity beginning as early as one day after symptoms first appear and lasting up to one week after treatment.<ref name="Schlossberg"> Schlossberg D. Clinical Infectious Disease. Cambridge University Press; 2008.</ref> [[Magnetic resonance imaging]] is the imaging modality of choice for herpes simplex encephalitis. The mainstay of therapy for herpes simplex encephalitis includes [[antiviral drug|antiviral]] therapy. The drug of choice is [[acyclovir]].<ref name="Mandell1"> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref>  


==Classification==
==Classification==
Line 15: Line 16:


==Pathophysiology==
==Pathophysiology==
The exact pathogenesis of herpes simplex encephalitis is not fully understood.<ref name=Schlossberg> Schlossberg D. Clinical Infectious Disease. Cambridge University Press; 2008.</ref> It is believed that herpes simplex encephalitis is caused by the [[Retrograde infection|retrograde transmission]] of the[[virus]] from a peripheral site on the face to the [[brain]] along a [[nerve]] [[axon]] following [[HSV-1]] reactivation.<ref name="pmid16675036"/> The [[virus]] lies dormant in the [[ganglion]] of the [[trigeminal]] or fifth [[cranial nerve]] but the exact pathogenesis remains unknown. The [[olfactory nerve]] may also be involved in herpes simplex encephalitis.<ref>{{cite journal | author = Dinn J | title = Transolfactory spread of virus in herpes simplex encephalitis. | journal = Br Med J | volume = 281 | issue = 6252 | pages = 1392 | year = 1980 | id = PMID 7437807}}</ref>
The exact pathogenesis of herpes simplex encephalitis is not fully understood.<ref name="Schlossberg"> Schlossberg D. Clinical Infectious Disease. Cambridge University Press; 2008.</ref> It is believed that herpes simplex encephalitis is caused by the [[Retrograde infection|retrograde transmission]] of the [[virus]] from a peripheral site on the face to the [[brain]] along a [[nerve]] [[axon]] following [[HSV-1]] reactivation.<ref name="pmid16675036" /> The [[virus]] lies dormant in the [[ganglion]] of the [[trigeminal]] or fifth [[cranial nerve]] but the exact pathogenesis remains unknown. The [[olfactory nerve]] may also be involved in herpes simplex encephalitis.<ref>{{cite journal | author = Dinn J | title = Transolfactory spread of virus in herpes simplex encephalitis. | journal = Br Med J | volume = 281 | issue = 6252 | pages = 1392 | year = 1980 | id = PMID 7437807}}</ref>


==Causes==
==Causes==
Line 21: Line 22:


==Differentiating Herpes simplex encephalitis from Other Diseases==
==Differentiating Herpes simplex encephalitis from Other Diseases==
Herpes simplex encephalitis must be differentiated from other diseases that cause [[fever]], [[headache]], and [[altered mental status]], such as:<ref name="pmid14978145">{{cite journal| author=Kennedy PG| title=Viral encephalitis: causes, differential diagnosis, and management. | journal=J Neurol Neurosurg Psychiatry | year= 2004 | volume= 75 Suppl 1 | issue=  | pages= i10-5 | pmid=14978145 | doi= | pmc=PMC1765650 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14978145  }} </ref><ref name= DAVIS> {{cite journal| author=Davis LE| title= Diagnosis and treatment of acute encephalitis. | journal= The Neurologist | year= 2000 | volume= 6 | issue= 3|}}</ref><ref name="pmid21932127">{{cite journal| author=Eckstein C, Saidha S, Levy M| title=A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. | journal=J Neurol | year= 2012 | volume= 259 | issue= 5 | pages= 801-16 | pmid=21932127 | doi=10.1007/s00415-011-6240-5 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21932127  }} </ref><ref name="pmid11260760">{{cite journal| author=De Kruijk JR, Twijnstra A, Leffers P| title=Diagnostic criteria and differential diagnosis of mild traumatic brain injury. | journal=Brain Inj | year= 2001 | volume= 15 | issue= 2 | pages= 99-106 | pmid=11260760 | doi=10.1080/026990501458335 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11260760  }} </ref>
Herpes simplex encephalitis must be differentiated from other diseases that cause [[fever]], [[headache]], and [[altered mental status]], such as:<ref name="pmid14978145">{{cite journal| author=Kennedy PG| title=Viral encephalitis: causes, differential diagnosis, and management. | journal=J Neurol Neurosurg Psychiatry | year= 2004 | volume= 75 Suppl 1 | issue=  | pages= i10-5 | pmid=14978145 | doi= | pmc=PMC1765650 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14978145  }} </ref><ref name="DAVIS"> {{cite journal| author=Davis LE| title= Diagnosis and treatment of acute encephalitis. | journal= The Neurologist | year= 2000 | volume= 6 | issue= 3|}}</ref><ref name="pmid21932127">{{cite journal| author=Eckstein C, Saidha S, Levy M| title=A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. | journal=J Neurol | year= 2012 | volume= 259 | issue= 5 | pages= 801-16 | pmid=21932127 | doi=10.1007/s00415-011-6240-5 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21932127  }} </ref><ref name="pmid11260760">{{cite journal| author=De Kruijk JR, Twijnstra A, Leffers P| title=Diagnostic criteria and differential diagnosis of mild traumatic brain injury. | journal=Brain Inj | year= 2001 | volume= 15 | issue= 2 | pages= 99-106 | pmid=11260760 | doi=10.1080/026990501458335 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11260760  }} </ref>


{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
|+
|+
! style="background: #4479BA; width: 50px;" | {{fontcolor|#FFF|Disease}}
! style="background: #4479BA; width: 50px;" |{{fontcolor|#FFF|Disease}}
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Similarities}}
! style="background: #4479BA; width: 100px;" |{{fontcolor|#FFF|Similarities}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Differentials}}
! style="background: #4479BA; width: 150px;" |{{fontcolor|#FFF|Differentials}}
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''[[Meningitis]]'''
| style="padding: 5px 5px; background: #DCDCDC;" |'''[[Meningitis]]'''
| style="padding: 5px 5px; background: #F5F5F5;" | Classic triad of [[fever]], [[nuchal rigidity]], and [[altered mental status]]
| style="padding: 5px 5px; background: #F5F5F5;" |Classic triad of [[fever]], [[nuchal rigidity]], and [[altered mental status]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Photophobia]], [[phonophobia]], [[rash]] associated with [[meningococcemia]], concomitant [[sinusitis]] or [[otitis]], swelling of the [[fontanelle]] in infants (0-6 months)
| style="padding: 5px 5px; background: #F5F5F5;" |[[Photophobia]], [[phonophobia]], [[rash]] associated with [[meningococcemia]], concomitant [[sinusitis]] or [[otitis]], swelling of the [[fontanelle]] in infants (0-6 months)
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |'''[[Brain abscess]]'''
| style="padding: 5px 5px; background: #DCDCDC;" |'''[[Brain abscess]]'''
| style="padding: 5px 5px; background: #F5F5F5;" | [[Fever]], [[headache]], [[hemiparesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Fever]], [[headache]], [[hemiparesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Varies depending on the location of the abscess; clinically, [[visual disturbance]] including [[papilledema]], decreased [[sensation]]; on imaging, a [[lesion]] demonstrates both ring enhancement and central restricted diffusion  
| style="padding: 5px 5px; background: #F5F5F5;" |Varies depending on the location of the abscess; clinically, [[visual disturbance]] including [[papilledema]], decreased [[sensation]]; on imaging, a [[lesion]] demonstrates both ring enhancement and central restricted diffusion
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''[[Demyelinating disease]]s'''
| style="padding: 5px 5px; background: #DCDCDC;" |'''[[Demyelinating disease]]s'''
| style="padding: 5px 5px; background: #F5F5F5;" | [[Ataxia]], [[lethargy]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Ataxia]], [[lethargy]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Multiple sclerosis]]: clinically, [[nystagmus]], [[internuclear ophthalmoplegia]], [[Lhermitte's sign]]; on imaging, well-demarcated ovoid lesions with possible T1 hypointensities (“black holes”)
| style="padding: 5px 5px; background: #F5F5F5;" |[[Multiple sclerosis]]: clinically, [[nystagmus]], [[internuclear ophthalmoplegia]], [[Lhermitte's sign]]; on imaging, well-demarcated ovoid lesions with possible T1 hypointensities (“black holes”)
[[Acute disseminated encephalomyelitis]]: clinically, [[somnolence]], [[myoclonic]] movements, and [[hemiparesis]]; on imaging, diffuse or multi-lesion enhancement, with indistinct lesion borders
[[Acute disseminated encephalomyelitis]]: clinically, [[somnolence]], [[myoclonic]] movements, and [[hemiparesis]]; on imaging, diffuse or multi-lesion enhancement, with indistinct lesion borders
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''[[Substance abuse]]'''
| style="padding: 5px 5px; background: #DCDCDC;" |'''[[Substance abuse]]'''
| style="padding: 5px 5px; background: #F5F5F5;" | [[Tremor]], [[headache]], [[altered mental status]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Tremor]], [[headache]], [[altered mental status]]
| style="padding: 5px 5px; background: #F5F5F5;" |Varies depending on type of substance: prior history, drug-seeking behavior, attention-seeking behavior, [[paranoia]], sudden [[panic]], [[anxiety]], [[hallucination]]s
| style="padding: 5px 5px; background: #F5F5F5;" |Varies depending on type of substance: prior history, drug-seeking behavior, attention-seeking behavior, [[paranoia]], sudden [[panic]], [[anxiety]], [[hallucination]]s
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''[[Electrolyte disturbance]]'''
| style="padding: 5px 5px; background: #DCDCDC;" |'''[[Electrolyte disturbance]]'''
| style="padding: 5px 5px; background: #F5F5F5;" | [[Fatigue]], [[headache]], [[nausea]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Fatigue]], [[headache]], [[nausea]]
| style="padding: 5px 5px; background: #F5F5F5;" |Varies depending on deficient ions; clinically, [[edema]], [[constipation]], [[hallucination]]s; on [[EKG]], abnormalities in [[T wave]], [[P wave]], [[QRS complex]]; possible presentations include [[arrhythmia]], [[dehydration]], [[renal failure]]
| style="padding: 5px 5px; background: #F5F5F5;" |Varies depending on deficient ions; clinically, [[edema]], [[constipation]], [[hallucination]]s; on [[EKG]], abnormalities in [[T wave]], [[P wave]], [[QRS complex]]; possible presentations include [[arrhythmia]], [[dehydration]], [[renal failure]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''[[Stroke]]'''
| style="padding: 5px 5px; background: #DCDCDC;" |'''[[Stroke]]'''
| style="padding: 5px 5px; background: #F5F5F5;" | [[Ataxia]], [[aphasia]], [[dizziness]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Ataxia]], [[aphasia]], [[dizziness]]
| style="padding: 5px 5px; background: #F5F5F5;" |Varies depending on classification of stroke; presents with positional [[vertigo]], high [[blood pressure]], [[extremities|extremity]] weakness
| style="padding: 5px 5px; background: #F5F5F5;" |Varies depending on classification of stroke; presents with positional [[vertigo]], high [[blood pressure]], [[extremities|extremity]] weakness
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''[[Intracranial hemorrhage]]'''
| style="padding: 5px 5px; background: #DCDCDC;" |'''[[Intracranial hemorrhage]]'''
| style="padding: 5px 5px; background: #F5F5F5;" | [[Headache]], [[coma]], [[dizziness]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Headache]], [[coma]], [[dizziness]]
| style="padding: 5px 5px; background: #F5F5F5;" | Lobar [[hemorrhage]], [[numbness]], [[tingling]], [[hypertension]], [[hemorrhagic diathesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |Lobar [[hemorrhage]], [[numbness]], [[tingling]], [[hypertension]], [[hemorrhagic diathesis]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''[[Trauma]]'''
| style="padding: 5px 5px; background: #DCDCDC;" |'''[[Trauma]]'''
| style="padding: 5px 5px; background: #F5F5F5;" | [[Headache]], [[altered mental status]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Headache]], [[altered mental status]]
| style="padding: 5px 5px; background: #F5F5F5;" | [[Amnesia]], [[loss of consciousness]], [[dizziness]], [[concussion]], [[contusion]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Amnesia]], [[loss of consciousness]], [[dizziness]], [[concussion]], [[contusion]]
|-
|-
|}
|}
Line 75: Line 76:
! rowspan="2" |<small>Other Findings</small>
! rowspan="2" |<small>Other Findings</small>
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
!<small>Na+, K+, Ca2+</small>  
!<small>Na+, K+, Ca2+</small>
!<small>CT /MRI</small>
!<small>CT /MRI</small>
!<small>CSF Findings</small>
!<small>CSF Findings</small>
Line 81: Line 82:
!<small>Neck stiffness</small>
!<small>Neck stiffness</small>
!<small>Motor or Sensory deficit</small>
!<small>Motor or Sensory deficit</small>
!<small>Papilledema</small>  
!<small>Papilledema</small>
!<small>Bulging fontanelle</small>
!<small>Bulging fontanelle</small>
!<small>Cranial nerves</small>
!<small>Cranial nerves</small>
Line 88: Line 89:
!<small>Altered mental status</small>
!<small>Altered mental status</small>
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Brain tumor|Brain tumour]]<ref name="pmid1278192">Soffer D (1976) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1278192 Brain tumors simulating purulent meningitis.] ''Eur Neurol'' 14 (3):192-7. PMID: [http://pubmed.gov/1278192 1278192]</ref><ref name="pmid3883130" />
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Brain tumor|Brain tumour]]<ref name="pmid1278192">Soffer D (1976) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1278192 Brain tumors simulating purulent meningitis.] ''Eur Neurol'' 14 (3):192-7. PMID: [http://pubmed.gov/1278192 1278192]</ref><ref name="pmid3883130" />
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px text-align:center" |Cancer cells<ref name="pmid21371327">{{cite journal| author=Weston CL, Glantz MJ, Connor JR| title=Detection of cancer cells in the cerebrospinal fluid: current methods and future directions. | journal=Fluids Barriers CNS | year= 2011 | volume= 8 | issue= 1 | pages= 14 | pmid=21371327 | doi=10.1186/2045-8118-8-14 | pmc=3059292 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21371327  }}</ref>
| style="background: #F5F5F5; padding: 5px text-align:center" |Cancer cells<ref name="pmid21371327">{{cite journal| author=Weston CL, Glantz MJ, Connor JR| title=Detection of cancer cells in the cerebrospinal fluid: current methods and future directions. | journal=Fluids Barriers CNS | year= 2011 | volume= 8 | issue= 1 | pages= 14 | pmid=21371327 | doi=10.1186/2045-8118-8-14 | pmc=3059292 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21371327  }}</ref>
| style="background: #F5F5F5; padding: 5px;" |MRI  
| style="background: #F5F5F5; padding: 5px;" |MRI
| style="background: #F5F5F5; padding: 5px; text-align:center" |    
| style="background: #F5F5F5; padding: 5px; text-align:center" |
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px;text-align:center" |?
| style="background: #F5F5F5; padding: 5px;text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |     ?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 113: Line 114:
| style="background: #F5F5F5; padding: 5px;text-align:center" |?
| style="background: #F5F5F5; padding: 5px;text-align:center" |?
| style="background: #F5F5F5; padding: 5px;text-align:center" |
| style="background: #F5F5F5; padding: 5px;text-align:center" |
| style="background: #F5F5F5; padding: 5px; text-align:center" |      ?
| style="background: #F5F5F5; padding: 5px; text-align:center" | ?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px;" |Alcohal intake, sudden witdrawl or reduction in consumption  
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px;" |Alcohal intake, sudden witdrawl or reduction in consumption
| style="background: #F5F5F5; padding: 5px;" |Tachycardia, diaphoresis, hypertension, tremors, mydriasis, positional nystagmus, tachypnea
| style="background: #F5F5F5; padding: 5px;" |Tachycardia, diaphoresis, hypertension, tremors, mydriasis, positional nystagmus, tachypnea
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Subarachnoid  hemorrhage]]<ref name="pmid14585453">Yeh ST, Lee WJ, Lin HJ, Chen CY, Te AL, Lin HJ (2003) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=14585453 Nonaneurysmal subarachnoid hemorrhage secondary to tuberculous meningitis: report of two cases.] ''J Emerg Med'' 25 (3):265-70. PMID: [http://pubmed.gov/14585453 14585453]</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Subarachnoid  hemorrhage]]<ref name="pmid14585453">Yeh ST, Lee WJ, Lin HJ, Chen CY, Te AL, Lin HJ (2003) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=14585453 Nonaneurysmal subarachnoid hemorrhage secondary to tuberculous meningitis: report of two cases.] ''J Emerg Med'' 25 (3):265-70. PMID: [http://pubmed.gov/14585453 14585453]</ref>


| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 130: Line 131:
| style="background: #F5F5F5; padding: 5px;text-align:center" |?
| style="background: #F5F5F5; padding: 5px;text-align:center" |?
| style="background: #F5F5F5; padding: 5px;text-align:center" |?
| style="background: #F5F5F5; padding: 5px;text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |     ?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
Line 137: Line 138:
| style="background: #F5F5F5; padding: 5px;" |Confusion, dizziness, nausea, vomiting
| style="background: #F5F5F5; padding: 5px;" |Confusion, dizziness, nausea, vomiting
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Stroke]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Stroke]]
| style="background: #F5F5F5; padding: 5px; text-align:center" |
| style="background: #F5F5F5; padding: 5px; text-align:center" |
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" | Normal
| style="background: #F5F5F5; padding: 5px; text-align:center" |Normal
| style="background: #F5F5F5; padding: 5px; text-align:center" | CT scan  without contrast
| style="background: #F5F5F5; padding: 5px; text-align:center" |CT scan  without contrast
| style="background: #F5F5F5; padding: 5px; text-align:center" |
| style="background: #F5F5F5; padding: 5px; text-align:center" |
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
Line 170: Line 171:
| style="background: #F5F5F5; padding: 5px;" |Blindness, confusion, [[depression]],
| style="background: #F5F5F5; padding: 5px;" |Blindness, confusion, [[depression]],


Abnormal [[gait]]  
Abnormal [[gait]]
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Viral encephalitis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Viral encephalitis]]
Line 181: Line 182:
| style="background: #F5F5F5; padding: 5px;text-align:center" |?
| style="background: #F5F5F5; padding: 5px;text-align:center" |?
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |   ?
| style="background: #F5F5F5; padding: 5px;" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px;" |?
| style="background: #F5F5F5; padding: 5px;" |?
Line 201: Line 202:
| style="background: #F5F5F5; padding: 5px;" |?
| style="background: #F5F5F5; padding: 5px;" |?
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |History of hypertension  
| style="background: #F5F5F5; padding: 5px;" |History of hypertension
| style="background: #F5F5F5; padding: 5px;" |Delirium, cortical blindness, cerebral edema, seizure
| style="background: #F5F5F5; padding: 5px;" |Delirium, cortical blindness, cerebral edema, seizure
|-
|-
Line 223: Line 224:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |?
| style="background: #F5F5F5; padding: 5px;" |?
| style="background: #F5F5F5; padding: 5px;" |'''?''' leukocytes >100,000/ul, '''?''' glucose and '''?''' protien, '''?''' red blood cells, lactic acid >500mg  
| style="background: #F5F5F5; padding: 5px;" |'''?''' leukocytes >100,000/ul, '''?''' glucose and '''?''' protien, '''?''' red blood cells, lactic acid >500mg
| style="background: #F5F5F5; padding: 5px;" |Contrast enhanced MRI is more sensitive and specific,
| style="background: #F5F5F5; padding: 5px;" |Contrast enhanced MRI is more sensitive and specific,
Histopathological examination of brain tissue
Histopathological examination of brain tissue
Line 253: Line 254:
| style="background: #F5F5F5; padding: 5px;" |Lithium, Sedatives, phenytoin, carbamazepine
| style="background: #F5F5F5; padding: 5px;" |Lithium, Sedatives, phenytoin, carbamazepine
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Conversion disorder]]  
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Conversion disorder]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 263: Line 264:
| style="background: #F5F5F5; padding: 5px;text-align:center" |?
| style="background: #F5F5F5; padding: 5px;text-align:center" |?
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px; text-align:center" | ?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
Line 294: Line 295:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px; text-align:center" |   ?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px;" |?
| style="background: #F5F5F5; padding: 5px;" |?
| style="background: #F5F5F5; padding: 5px;" |?
| style="background: #F5F5F5; padding: 5px;" |?
| style="background: #F5F5F5; padding: 5px;" |Family history of febrile seizures, viral illness or gastroenteritis
| style="background: #F5F5F5; padding: 5px;" |Family history of febrile seizures, viral illness or gastroenteritis
| style="background: #F5F5F5; padding: 5px;" |Age > 1 month,  
| style="background: #F5F5F5; padding: 5px;" |Age > 1 month,
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Subdural empyema]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Subdural empyema]]
Line 305: Line 306:
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |
| style="background: #F5F5F5; padding: 5px; text-align:center" |
| style="background: #F5F5F5; padding: 5px;" |Clinical assesment and [[MRI]]  
| style="background: #F5F5F5; padding: 5px;" |Clinical assesment and [[MRI]]
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
Line 317: Line 318:
| style="background: #F5F5F5; padding: 5px;" |Blurry vision, [[urinary incontinence]], [[fatigue]]
| style="background: #F5F5F5; padding: 5px;" |Blurry vision, [[urinary incontinence]], [[fatigue]]
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hypoglycemia]]  
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hypoglycemia]]
| style="background: #F5F5F5; padding: 5px; text-align:center" |? or '''?'''
| style="background: #F5F5F5; padding: 5px; text-align:center" |? or '''?'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 328: Line 329:
| style="background: #F5F5F5; padding: 5px;text-align:center" |
| style="background: #F5F5F5; padding: 5px;text-align:center" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px; text-align:center" | ?
| style="background: #F5F5F5; padding: 5px; text-align:center" |?
| style="background: #F5F5F5; padding: 5px; text-align:center" |
| style="background: #F5F5F5; padding: 5px; text-align:center" |
| style="background: #F5F5F5; padding: 5px;" |?
| style="background: #F5F5F5; padding: 5px;" |?
Line 337: Line 338:
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
The incidence of herpes simplex encephalitis is approximately 0.1-0.2 per 100,000 individuals worldwide.<ref name="pmid16675036">{{cite journal |author=Whitley RJ |title=Herpes simplex encephalitis: adolescents and adults |journal=Antiviral Res. |volume=71 |issue=2-3 |pages=141–8 |year=2006 |pmid=16675036 |doi=10.1016/j.antiviral.2006.04.002}}</ref><ref name="pmid14978145">{{cite journal| author=Kennedy PG| title=Viral encephalitis: causes, differential diagnosis, and management. | journal=J Neurol Neurosurg Psychiatry | year= 2004 | volume= 75 Suppl 1 | issue=  | pages= i10-5 | pmid=14978145 | doi= | pmc=PMC1765650 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14978145  }} </ref> Approximately 2,000 cases of herpes simplex encephalitis occur within the United States annually.<ref name=Mandell1> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref> Approximately 90% of cases are caused by [[HSV-1]], with 10% caused by [[HSV-2]]. [[HSV-2]] infection is most commonly observed among [[immunocompromised]] individuals and [[neonates]].
The incidence of herpes simplex encephalitis is approximately 0.1-0.2 per 100,000 individuals worldwide.<ref name="pmid16675036">{{cite journal |author=Whitley RJ |title=Herpes simplex encephalitis: adolescents and adults |journal=Antiviral Res. |volume=71 |issue=2-3 |pages=141–8 |year=2006 |pmid=16675036 |doi=10.1016/j.antiviral.2006.04.002}}</ref><ref name="pmid14978145">{{cite journal| author=Kennedy PG| title=Viral encephalitis: causes, differential diagnosis, and management. | journal=J Neurol Neurosurg Psychiatry | year= 2004 | volume= 75 Suppl 1 | issue=  | pages= i10-5 | pmid=14978145 | doi= | pmc=PMC1765650 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14978145  }} </ref> Approximately 2,000 cases of herpes simplex encephalitis occur within the United States annually.<ref name="Mandell1"> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref> Approximately 90% of cases are caused by [[HSV-1]], with 10% caused by [[HSV-2]]. [[HSV-2]] infection is most commonly observed among [[immunocompromised]] individuals and [[neonates]].


===Age===
===Age===
Line 343: Line 344:


===Gender===
===Gender===
There is no gender predilection to the development of herpes simplex encephalitis.<ref name=Mandell1> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref>
There is no gender predilection to the development of herpes simplex encephalitis.<ref name="Mandell1"> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref>


===Race===
===Race===
There is no racial predilection to the development of herpes simplex encephalitis.<ref name=Mandell1> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref>
There is no racial predilection to the development of herpes simplex encephalitis.<ref name="Mandell1"> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref>


===Season===
===Season===
Unlike other cases of encephalitis, there is no seasonal predilection to the development of herpes simplex encephalitis.<ref name=Mandell1> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref>
Unlike other cases of encephalitis, there is no seasonal predilection to the development of herpes simplex encephalitis.<ref name="Mandell1"> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref>


==Risk Factors==
==Risk Factors==
The most potent risk factor in the development of herpes simplex encephalitis is [[immune deficiency]]. Other risk factors include [[age]] and extent of human contact.<ref name=Mandell1> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref><ref name= NINDS> Meningitis and Encephalitis Fact Sheet. National Institute of Neurological Disorders and Stroke. National Institutes of Health (2015). http://www.ninds.nih.gov/disorders/encephalitis_meningitis/detail_encephalitis_meningitis.htm Accessed on February 9, 2015 </ref>
The most potent risk factor in the development of herpes simplex encephalitis is [[immune deficiency]]. Other risk factors include [[age]] and extent of human contact.<ref name="Mandell1"> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref><ref name="NINDS"> Meningitis and Encephalitis Fact Sheet. National Institute of Neurological Disorders and Stroke. National Institutes of Health (2015). http://www.ninds.nih.gov/disorders/encephalitis_meningitis/detail_encephalitis_meningitis.htm Accessed on February 9, 2015 </ref>


==Natural History, Complications and Prognosis==
==Natural History, Complications and Prognosis==
Line 359: Line 360:


===Complications===
===Complications===
Common complications of herpes simplex encephalitis include:<ref name= NINDS> Meningitis and Encephalitis Fact Sheet. National Institute of Neurological Disorders and Stroke. National Institutes of Health (2015). http://www.ninds.nih.gov/disorders/encephalitis_meningitis/detail_encephalitis_meningitis.htm Accessed on February 9, 2015 </ref>
Common complications of herpes simplex encephalitis include:<ref name="NINDS"> Meningitis and Encephalitis Fact Sheet. National Institute of Neurological Disorders and Stroke. National Institutes of Health (2015). http://www.ninds.nih.gov/disorders/encephalitis_meningitis/detail_encephalitis_meningitis.htm Accessed on February 9, 2015 </ref>
 
*[[Meningitis]]
*[[Meningitis]]
*Increased [[intracranial pressure]]
*Increased [[intracranial pressure]]
Line 373: Line 375:
==Diagnosis==
==Diagnosis==
===Diagnostic Criteria===
===Diagnostic Criteria===
The diagnosis of herpes simplex encephalitis is based on the [[IDSA guidelines classification scheme|IDSA]] criteria, which can be found [http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/Encephalitis.pdf here].<ref name=IDSAEnceph> The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America. http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/Encephalitis.pdf Accessed on February 16, 2016.</ref>
The diagnosis of herpes simplex encephalitis is based on the [[IDSA guidelines classification scheme|IDSA]] criteria, which can be found [http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/Encephalitis.pdf here].<ref name="IDSAEnceph"> The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America. http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/Encephalitis.pdf Accessed on February 16, 2016.</ref>


===History and Symptoms===
===History and Symptoms===
If possible, a detailed and thorough history from the patient is necessary. Symptoms of herpes simplex encephalitis include:<ref name=Mandell1> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref>
If possible, a detailed and thorough history from the patient is necessary. Symptoms of herpes simplex encephalitis include:<ref name="Mandell1"> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref>
 
*[[alertness|Decreased alertness]]
*[[alertness|Decreased alertness]]
*[[Confusion]]
*[[Confusion]]
Line 389: Line 392:
===Physical Examination===
===Physical Examination===
Physical examination findings for herpes simplex encephalitis are generally unspecific. Common physical examination findings of herpes simplex encephalitis include:
Physical examination findings for herpes simplex encephalitis are generally unspecific. Common physical examination findings of herpes simplex encephalitis include:
*[[Fever]]
*[[Fever]]
*[[Confusion]]
*[[Confusion]]
Line 399: Line 403:


===Laboratory Findings===
===Laboratory Findings===
Laboratory findings consistent with the diagnosis of herpes simplex encephalitis include increased [[leukocytes]] in [[cerebrospinal fluid]] obtained via [[lumbar puncture]].<ref name="pmid11853816">{{cite journal |author=Whitley RJ, Gnann JW |title=Viral encephalitis: familiar infections and emerging pathogens |journal=Lancet |volume=359 |issue=9305 |pages=507–13 |year=2002 |pmid=11853816 |doi=}}</ref> [[Polymerase chain reaction]] is critical in the diagnosis of herpes simplex encephalitis, as there is a 95-98% specificity and sensitivity beginning as early as one day after symptoms first appear and lasting up to one week after treatment.<ref name=Schlossberg> Schlossberg D. Clinical Infectious Disease. Cambridge University Press; 2008.</ref>
Laboratory findings consistent with the diagnosis of herpes simplex encephalitis include increased [[leukocytes]] in [[cerebrospinal fluid]] obtained via [[lumbar puncture]].<ref name="pmid11853816">{{cite journal |author=Whitley RJ, Gnann JW |title=Viral encephalitis: familiar infections and emerging pathogens |journal=Lancet |volume=359 |issue=9305 |pages=507–13 |year=2002 |pmid=11853816 |doi=}}</ref> [[Polymerase chain reaction]] is critical in the diagnosis of herpes simplex encephalitis, as there is a 95-98% specificity and sensitivity beginning as early as one day after symptoms first appear and lasting up to one week after treatment.<ref name="Schlossberg"> Schlossberg D. Clinical Infectious Disease. Cambridge University Press; 2008.</ref>


===CT===
===CT===
[[Computed tomography]] may be helpful in the diagnosis of herpes simplex encephalitis. Findings on [[CT]] suggestive of herpes simplex encephalitis include subtle low density within the [[anterior]] and [[medial]] [[temporal lobe]] and the [[insular cortex]].<ref name=RadioHSE> Herpes simplex encephalitis. Radiopaedia.org (2016). http://radiopaedia.org/articles/herpes-simplex-encephalitis Accessed on February 9, 2016. </ref><ref name="pmid6766039">{{cite journal| author=Zimmerman RD, Russell EJ, Leeds NE, Kaufman D| title=CT in the early diagnosis of herpes simplex encephalitis. | journal=AJR Am J Roentgenol | year= 1980 | volume= 134 | issue= 1 | pages= 61-6 | pmid=6766039 | doi=10.2214/ajr.134.1.61 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6766039  }} </ref> Subtleties become more apparent over time and may progress to [[hemorrhage]], and may eventually spread to the other [[temporal lobe]] after 7-10 days.<ref name="pmid11853816">{{cite journal |author=Whitley RJ, Gnann JW |title=Viral encephalitis: familiar infections and emerging pathogens |journal=Lancet |volume=359 |issue=9305 |pages=507–13 |year=2002 |pmid=11853816 |doi=}}</ref>   
[[Computed tomography]] may be helpful in the diagnosis of herpes simplex encephalitis. Findings on [[CT]] suggestive of herpes simplex encephalitis include subtle low density within the [[anterior]] and [[medial]] [[temporal lobe]] and the [[insular cortex]].<ref name="RadioHSE"> Herpes simplex encephalitis. Radiopaedia.org (2016). http://radiopaedia.org/articles/herpes-simplex-encephalitis Accessed on February 9, 2016. </ref><ref name="pmid6766039">{{cite journal| author=Zimmerman RD, Russell EJ, Leeds NE, Kaufman D| title=CT in the early diagnosis of herpes simplex encephalitis. | journal=AJR Am J Roentgenol | year= 1980 | volume= 134 | issue= 1 | pages= 61-6 | pmid=6766039 | doi=10.2214/ajr.134.1.61 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6766039  }} </ref> Subtleties become more apparent over time and may progress to [[hemorrhage]], and may eventually spread to the other [[temporal lobe]] after 7-10 days.<ref name="pmid11853816">{{cite journal |author=Whitley RJ, Gnann JW |title=Viral encephalitis: familiar infections and emerging pathogens |journal=Lancet |volume=359 |issue=9305 |pages=507–13 |year=2002 |pmid=11853816 |doi=}}</ref>   


===MRI===
===MRI===
[[Magnetic resonance imaging]] is the imaging modality of choice for herpes simplex encephalitis. Findings on [[MRI]] suggestive of herpes simplex encephalitis include:<ref name=RadioHSE> Herpes simplex encephalitis. Radiopaedia.org (2016). http://radiopaedia.org/articles/herpes-simplex-encephalitis Accessed on February 9, 2016. </ref><ref name="pmid18319155">{{cite journal| author=Bulakbasi N, Kocaoglu M| title=Central nervous system infections of herpesvirus family. | journal=Neuroimaging Clin N Am | year= 2008 | volume= 18 | issue= 1 | pages= 53-84; viii | pmid=18319155 | doi=10.1016/j.nic.2007.12.001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18319155  }} </ref>
[[Magnetic resonance imaging]] is the imaging modality of choice for herpes simplex encephalitis. Findings on [[MRI]] suggestive of herpes simplex encephalitis include:<ref name="RadioHSE"> Herpes simplex encephalitis. Radiopaedia.org (2016). http://radiopaedia.org/articles/herpes-simplex-encephalitis Accessed on February 9, 2016. </ref><ref name="pmid18319155">{{cite journal| author=Bulakbasi N, Kocaoglu M| title=Central nervous system infections of herpesvirus family. | journal=Neuroimaging Clin N Am | year= 2008 | volume= 18 | issue= 1 | pages= 53-84; viii | pmid=18319155 | doi=10.1016/j.nic.2007.12.001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18319155  }} </ref>
 
*T1
*T1
**General [[edema]] in the affected region
**General [[edema]] in the affected region
**Hyperintense signal if complicated by [[subacute]] [[hemorrhage]]
**Hyperintense signal if complicated by [[subacute]] [[hemorrhage|hemorrhage.]]
*T1 C+ (Gd)
*T1 C+ (Gd)
**Early, enhancement is generally absent
**Early: enhancement is generally absent.
**Later, enhancement is variable and may appear as:
**Later: enhancement is variable and may appear as:
***Gyral enhancement
***Gyral enhancement
***[[Leptomeningeal]] enhancement  
***[[Leptomeningeal]] enhancement
***Ring enhancement
***Ring enhancement
***Diffuse enhancement
***Diffuse enhancement
*T2
*T2
**Hyperintensity of affected [[white matter]] and [[cerebral cortex]]
**Hyperintensity of affected [[white matter]] and [[cerebral cortex|cerebral cortex.]]
*DWI/ADC
*DWI/ADC
**More sensitive than T2 weighted images
**More sensitive than T2 weighted images.
**Restricted diffusion is common due to [[cytotoxic]] [[edema]]
**Restricted diffusion is common due to [[cytotoxic]] [[edema|edema.]]
*GE/SWI
*GE/SWI
**May demonstrate blooming if [[hemorrhagic]]
**May demonstrate blooming if [[hemorrhagic|hemorrhagic.]]


The following video demonstrates herpes simplex encephalitis on MRI:
The following video demonstrates herpes simplex encephalitis on MRI:


{{#ev:youtube|OLQlsDCcD3Y}}
{{#ev:youtube|OLQlsDCcD3Y}}
<br clear:"left"/>
<br clear:"left" />
==Treatment==
==Treatment==
===Medical Therapy===
===Medical Therapy===
The mainstay of therapy for herpes simplex encephalitis includes [[antiviral drug|antiviral]] therapy. The drug of choice is [[acyclovir]].<ref name=Mandell1> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref> Supportive therapy for herpes simplex encephalitis includes breathing assistance, [[intravenous fluids]], [[anti-inflammatory drug]]s, and [[anticonvulsant]] medication.<ref name=MAYOClinic> Encephalitis: Treatment and drugs. Mayo Clinic. http://www.mayoclinic.org/diseases-conditions/encephalitis/basics/treatment/con-20021917 Accessed on February 11, 2016 </ref>
The mainstay of therapy for herpes simplex encephalitis includes [[antiviral drug|antiviral]] therapy. The drug of choice is [[acyclovir]].<ref name="Mandell1"> M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.</ref> Supportive therapy for herpes simplex encephalitis includes breathing assistance, [[intravenous fluids]], [[anti-inflammatory drug]]s, and [[anticonvulsant]] medication.<ref name="MAYOClinic"> Encephalitis: Treatment and drugs. Mayo Clinic. http://www.mayoclinic.org/diseases-conditions/encephalitis/basics/treatment/con-20021917 Accessed on February 11, 2016 </ref>


===Primary Prevention===
===Primary Prevention===

Latest revision as of 06:10, 13 June 2021


Template:DiseaseDisorder infobox

Sexually transmitted diseases Main Page

Herpes simplex Microchapters

Home

Patient Information

Genital Herpes
Congenital Herpes

Overview

Classification

Orofacial Infection
Anogenital Infection
Ocular Infection
Herpes Encephalitis
Neonatal Herpes
Herpetic Whitlow
Herpes Gladiatorum
Mollaret's Meningitis

Pathophysiology

Epidemiology and Demographics

Asymptomatic Shedding

Recurrences and Triggers

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Direct detection of Genital Lesions

Treatment

Antiviral Therapy

Overview
Antivirals for First Episode of Genital Herpes
Antivirals for Recurrent Genital Herpes

Primary Prevention

Counseling

Herpes simplex encephalitis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Herpes simplex encephalitis

CDC on Herpes simplex encephalitis

Herpes simplex encephalitis in the news

Blogs on Herpes simplex encephalitis

Directions to Hospitals Treating Herpes simplex

Risk calculators and risk factors for Herpes simplex encephalitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2], Anthony Gallo, B.S. [3]

Synonyms and keywords: HSE; Herpes viral encephalitis; Herpes meningoencephalitis

Overview

Herpes simplex encephalitis is a severe viral infection of the central nervous system. Herpes simplex encephalitis may be classified according to the origin of the disease into two subtypes: oral (HSV-1) and genital (HSV-2). The exact pathogenesis of herpes simplex encephalitis is not fully understood.[1] Herpes simplex encephalitis must be differentiated from other diseases that cause fever, headache, and altered mental status. Physical examination findings for herpes simplex encephalitis are generally unspecific. Herpes simplex encephalitis constitutes a medical emergency. If left untreated, approximately 70% patients with herpes simplex encephalitis progress to mortality.[2] Common complications of herpes simplex encephalitis include meningitis, increased intracranial pressure, and coma. Laboratory findings consistent with the diagnosis of herpes simplex encephalitis include increased leukocytes in cerebrospinal fluid.[3] Polymerase chain reaction is critical in the diagnosis of herpes simplex encephalitis, as there is a 95-98% specificity and sensitivity beginning as early as one day after symptoms first appear and lasting up to one week after treatment.[1] Magnetic resonance imaging is the imaging modality of choice for herpes simplex encephalitis. The mainstay of therapy for herpes simplex encephalitis includes antiviral therapy. The drug of choice is acyclovir.[4]

Classification

Herpes simplex encephalitis may be classified according to origin of disease into two subtypes: oral (HSV-1) and genital (HSV-2).

Pathophysiology

The exact pathogenesis of herpes simplex encephalitis is not fully understood.[1] It is believed that herpes simplex encephalitis is caused by the retrograde transmission of the virus from a peripheral site on the face to the brain along a nerve axon following HSV-1 reactivation.[2] The virus lies dormant in the ganglion of the trigeminal or fifth cranial nerve but the exact pathogenesis remains unknown. The olfactory nerve may also be involved in herpes simplex encephalitis.[5]

Causes

Herpes simplex encephalitis may be caused by either HSV-1 or HSV-2.

Differentiating Herpes simplex encephalitis from Other Diseases

Herpes simplex encephalitis must be differentiated from other diseases that cause fever, headache, and altered mental status, such as:[6][7][8][9]

Disease Similarities Differentials
Meningitis Classic triad of fever, nuchal rigidity, and altered mental status Photophobia, phonophobia, rash associated with meningococcemia, concomitant sinusitis or otitis, swelling of the fontanelle in infants (0-6 months)
Brain abscess Fever, headache, hemiparesis Varies depending on the location of the abscess; clinically, visual disturbance including papilledema, decreased sensation; on imaging, a lesion demonstrates both ring enhancement and central restricted diffusion
Demyelinating diseases Ataxia, lethargy Multiple sclerosis: clinically, nystagmus, internuclear ophthalmoplegia, Lhermitte's sign; on imaging, well-demarcated ovoid lesions with possible T1 hypointensities (“black holes”)

Acute disseminated encephalomyelitis: clinically, somnolence, myoclonic movements, and hemiparesis; on imaging, diffuse or multi-lesion enhancement, with indistinct lesion borders

Substance abuse Tremor, headache, altered mental status Varies depending on type of substance: prior history, drug-seeking behavior, attention-seeking behavior, paranoia, sudden panic, anxiety, hallucinations
Electrolyte disturbance Fatigue, headache, nausea Varies depending on deficient ions; clinically, edema, constipation, hallucinations; on EKG, abnormalities in T wave, P wave, QRS complex; possible presentations include arrhythmia, dehydration, renal failure
Stroke Ataxia, aphasia, dizziness Varies depending on classification of stroke; presents with positional vertigo, high blood pressure, extremity weakness
Intracranial hemorrhage Headache, coma, dizziness Lobar hemorrhage, numbness, tingling, hypertension, hemorrhagic diathesis
Trauma Headache, altered mental status Amnesia, loss of consciousness, dizziness, concussion, contusion

Herpes simplex encephalitis must be differentiated from other causes of headache, altered mental status and seizures such as brain tumors and delirium trmemns.

Diseases Diagnostic tests Physical Examination Symptoms Past medical history Other Findings
Na+, K+, Ca2+ CT /MRI CSF Findings Gold standard test Neck stiffness Motor or Sensory deficit Papilledema Bulging fontanelle Cranial nerves Headache Fever Altered mental status
Brain tumour[10][11] ? Cancer cells[12] MRI ? ? ? ? ? ? Cachexia, gradual progression of symptoms
Delerium Tremens ? Clinical diagnosis ? ? ? ? ? ? Alcohal intake, sudden witdrawl or reduction in consumption Tachycardia, diaphoresis, hypertension, tremors, mydriasis, positional nystagmus, tachypnea
Subarachnoid hemorrhage[13] ? Xanthochromia[14] CT scan without contrast[15][16] ? ? ? ? ? ? ? ? Trauma/fall Confusion, dizziness, nausea, vomiting
Stroke ? Normal CT scan without contrast ? ? ? ? ? TIAs, hypertension, diabetes mellitus Speech difficulty, gait abnormality
Neurosyphilis[17][18] ? ? Leukocytes and protein CSF VDRL-specifc

CSF FTA-Ab -sensitive[19]

? ? ? ? ? ? Unprotected sexual intercourse, STIs Blindness, confusion, depression,

Abnormal gait

Viral encephalitis ? Increased RBCS or xanthochromia, mononuclear lymphocytosis, high protein content, normal glucose Clinical assesment ? ? ? ? ? ? ? Tick bite/mosquito bite/ viral prodome for several days Extreme lethargy, rash hepatosplenomegaly, lymphadenopathy, behavioural changes
Herpes simplex encephalitis ? Clinical assesment ? ? ? ? ? History of hypertension Delirium, cortical blindness, cerebral edema, seizure
Wernicke’s encephalopathy Normal ? ? ? History of alcohal abuse Ophthalmoplegia, confusion
CNS abscess ? ? leukocytes >100,000/ul, ? glucose and ? protien, ? red blood cells, lactic acid >500mg Contrast enhanced MRI is more sensitive and specific,

Histopathological examination of brain tissue

? ? ? ? ? ? ? History of drug abuse, endocarditis, ? immune status High grade fever, fatigue,nausea, vomiting
Drug toxicity ? ? Lithium, Sedatives, phenytoin, carbamazepine
Conversion disorder Diagnosis of exclusion ? ? ? ? ? Tremors, blindness, difficulty swallowing
Electrolyte disturbance ? or ? Depends on the cause ? ? Confusion, seizures
Febrile seizures Not performed in first simple febrile seizures Clinical diagnosis and EEG ? ? ? ? Family history of febrile seizures, viral illness or gastroenteritis Age > 1 month,
Subdural empyema ? Clinical assesment and MRI ? ? ? ? ? ? History of relapses and remissions Blurry vision, urinary incontinence, fatigue
Hypoglycemia ? or ? Serum blood glucose

HbA1c

? ? ? History of diabetes Palpitations, sweating, dizziness, low serum, glucose

Epidemiology and Demographics

Incidence

The incidence of herpes simplex encephalitis is approximately 0.1-0.2 per 100,000 individuals worldwide.[2][6] Approximately 2,000 cases of herpes simplex encephalitis occur within the United States annually.[4] Approximately 90% of cases are caused by HSV-1, with 10% caused by HSV-2. HSV-2 infection is most commonly observed among immunocompromised individuals and neonates.

Age

Approximately 50% of individuals who develop herpes simplex encephalitis are over 50 years of age.[3]

Gender

There is no gender predilection to the development of herpes simplex encephalitis.[4]

Race

There is no racial predilection to the development of herpes simplex encephalitis.[4]

Season

Unlike other cases of encephalitis, there is no seasonal predilection to the development of herpes simplex encephalitis.[4]

Risk Factors

The most potent risk factor in the development of herpes simplex encephalitis is immune deficiency. Other risk factors include age and extent of human contact.[4][20]

Natural History, Complications and Prognosis

Natural History

Herpes simplex encephalitis constitutes a medical emergency. If left untreated, approximately 70% patients with herpes simplex encephalitis progress to mortality.[2]

Complications

Common complications of herpes simplex encephalitis include:[20]

Prognosis

The prognosis for herpes simplex encephalitis is generally poor. Even with rapid treatment, it is fatal in approximately 20% of cases. In approximately 50% of surviving patients, long-term neurological damage is present. Only 2.5% of survivors regain full brain function.[3]

Diagnosis

Diagnostic Criteria

The diagnosis of herpes simplex encephalitis is based on the IDSA criteria, which can be found here.[21]

History and Symptoms

If possible, a detailed and thorough history from the patient is necessary. Symptoms of herpes simplex encephalitis include:[4]

Physical Examination

Physical examination findings for herpes simplex encephalitis are generally unspecific. Common physical examination findings of herpes simplex encephalitis include:

Laboratory Findings

Laboratory findings consistent with the diagnosis of herpes simplex encephalitis include increased leukocytes in cerebrospinal fluid obtained via lumbar puncture.[3] Polymerase chain reaction is critical in the diagnosis of herpes simplex encephalitis, as there is a 95-98% specificity and sensitivity beginning as early as one day after symptoms first appear and lasting up to one week after treatment.[1]

CT

Computed tomography may be helpful in the diagnosis of herpes simplex encephalitis. Findings on CT suggestive of herpes simplex encephalitis include subtle low density within the anterior and medial temporal lobe and the insular cortex.[22][23] Subtleties become more apparent over time and may progress to hemorrhage, and may eventually spread to the other temporal lobe after 7-10 days.[3]

MRI

Magnetic resonance imaging is the imaging modality of choice for herpes simplex encephalitis. Findings on MRI suggestive of herpes simplex encephalitis include:[22][24]

  • T1
  • T1 C+ (Gd)
    • Early: enhancement is generally absent.
    • Later: enhancement is variable and may appear as:
      • Gyral enhancement
      • Leptomeningeal enhancement
      • Ring enhancement
      • Diffuse enhancement
  • T2
  • DWI/ADC
    • More sensitive than T2 weighted images.
    • Restricted diffusion is common due to cytotoxic edema.
  • GE/SWI

The following video demonstrates herpes simplex encephalitis on MRI:

{{#ev:youtube|OLQlsDCcD3Y}}

Treatment

Medical Therapy

The mainstay of therapy for herpes simplex encephalitis includes antiviral therapy. The drug of choice is acyclovir.[4] Supportive therapy for herpes simplex encephalitis includes breathing assistance, intravenous fluids, anti-inflammatory drugs, and anticonvulsant medication.[25]

Primary Prevention

Effective measures for the primary prevention of herpes simplex encephalitis include abstinence from sexual contact, remaining in a long-term mutually monogamous relationship with an uninfected partner, use of latex condoms, and conversing with possible sexual partners regarding infections. Vaccines against herpes simplex have been developed but remain experimental.

References

  1. 1.0 1.1 1.2 1.3 Schlossberg D. Clinical Infectious Disease. Cambridge University Press; 2008.
  2. 2.0 2.1 2.2 2.3 Whitley RJ (2006). "Herpes simplex encephalitis: adolescents and adults". Antiviral Res. 71 (2–3): 141–8. doi:10.1016/j.antiviral.2006.04.002. PMID 16675036.
  3. 3.0 3.1 3.2 3.3 3.4 Whitley RJ, Gnann JW (2002). "Viral encephalitis: familiar infections and emerging pathogens". Lancet. 359 (9305): 507–13. PMID 11853816.
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 M.D. JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Expert Consult Premium Edition. Saunders; 2014.
  5. Dinn J (1980). "Transolfactory spread of virus in herpes simplex encephalitis". Br Med J. 281 (6252): 1392. PMID 7437807.
  6. 6.0 6.1 Kennedy PG (2004). "Viral encephalitis: causes, differential diagnosis, and management". J Neurol Neurosurg Psychiatry. 75 Suppl 1: i10–5. PMC 1765650. PMID 14978145.
  7. Davis LE (2000). "Diagnosis and treatment of acute encephalitis". The Neurologist. 6 (3).
  8. Eckstein C, Saidha S, Levy M (2012). "A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis". J Neurol. 259 (5): 801–16. doi:10.1007/s00415-011-6240-5. PMID 21932127.
  9. De Kruijk JR, Twijnstra A, Leffers P (2001). "Diagnostic criteria and differential diagnosis of mild traumatic brain injury". Brain Inj. 15 (2): 99–106. doi:10.1080/026990501458335. PMID 11260760.
  10. Soffer D (1976) Brain tumors simulating purulent meningitis. Eur Neurol 14 (3):192-7. PMID: 1278192
  11. Weston CL, Glantz MJ, Connor JR (2011). "Detection of cancer cells in the cerebrospinal fluid: current methods and future directions". Fluids Barriers CNS. 8 (1): 14. doi:10.1186/2045-8118-8-14. PMC 3059292. PMID 21371327.
  12. Yeh ST, Lee WJ, Lin HJ, Chen CY, Te AL, Lin HJ (2003) Nonaneurysmal subarachnoid hemorrhage secondary to tuberculous meningitis: report of two cases. J Emerg Med 25 (3):265-70. PMID: 14585453
  13. Lee MC, Heaney LM, Jacobson RL, Klassen AC (1975). "Cerebrospinal fluid in cerebral hemorrhage and infarction". Stroke. 6 (6): 638–41. PMID 1198628.
  14. Birenbaum D, Bancroft LW, Felsberg GJ (2011). "Imaging in acute stroke". West J Emerg Med. 12 (1): 67–76. PMC 3088377. PMID 21694755.
  15. DeLaPaz RL, Wippold FJ, Cornelius RS, Amin-Hanjani S, Angtuaco EJ, Broderick DF; et al. (2011). "ACR Appropriateness Criteria® on cerebrovascular disease". J Am Coll Radiol. 8 (8): 532–8. doi:10.1016/j.jacr.2011.05.010. PMID 21807345.
  16. Liu LL, Zheng WH, Tong ML, Liu GL, Zhang HL, Fu ZG; et al. (2012). "Ischemic stroke as a primary symptom of neurosyphilis among HIV-negative emergency patients". J Neurol Sci. 317 (1–2): 35–9. doi:10.1016/j.jns.2012.03.003. PMID 22482824.
  17. Berger JR, Dean D (2014). "Neurosyphilis". Handb Clin Neurol. 121: 1461–72. doi:10.1016/B978-0-7020-4088-7.00098-5. PMID 24365430.
  18. Ho EL, Marra CM (2012). "Treponemal tests for neurosyphilis--less accurate than what we thought?". Sex Transm Dis. 39 (4): 298–9. doi:10.1097/OLQ.0b013e31824ee574. PMC 3746559. PMID 22421697.
  19. 20.0 20.1 Meningitis and Encephalitis Fact Sheet. National Institute of Neurological Disorders and Stroke. National Institutes of Health (2015). http://www.ninds.nih.gov/disorders/encephalitis_meningitis/detail_encephalitis_meningitis.htm Accessed on February 9, 2015
  20. The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America. http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/Encephalitis.pdf Accessed on February 16, 2016.
  21. 22.0 22.1 Herpes simplex encephalitis. Radiopaedia.org (2016). http://radiopaedia.org/articles/herpes-simplex-encephalitis Accessed on February 9, 2016.
  22. Zimmerman RD, Russell EJ, Leeds NE, Kaufman D (1980). "CT in the early diagnosis of herpes simplex encephalitis". AJR Am J Roentgenol. 134 (1): 61–6. doi:10.2214/ajr.134.1.61. PMID 6766039.
  23. Bulakbasi N, Kocaoglu M (2008). "Central nervous system infections of herpesvirus family". Neuroimaging Clin N Am. 18 (1): 53–84, viii. doi:10.1016/j.nic.2007.12.001. PMID 18319155.
  24. Encephalitis: Treatment and drugs. Mayo Clinic. http://www.mayoclinic.org/diseases-conditions/encephalitis/basics/treatment/con-20021917 Accessed on February 11, 2016